{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:19:34Z","timestamp":1787566774452,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Advanced Accelerator Applications SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018720","name":"Advanced Accelerator Applications","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018720","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eclinm.2026.104109","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:46:19Z","timestamp":1786124779000},"page":"104109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2\u20133, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial"],"prefix":"10.1016","volume":"98","author":[{"given":"Diego","family":"Ferone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Myrehaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-930X","authenticated-orcid":false,"given":"Daniel","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Chasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7160-8908","authenticated-orcid":false,"given":"Amparo","family":"Garc\u00eda-Burillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secondo","family":"Lastoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Sansovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Filice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Folitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104109_bib1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eclinm.2026.104109_bib2","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-14-0354","article-title":"GEP-NETs update: biotherapy for neuroendocrine tumours","volume":"172","author":"Alonso-Gordoa","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eclinm.2026.104109_bib3","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.104109_bib4","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104109_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/ERC-20-0340","article-title":"Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging","volume":"27","author":"Refardt","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eclinm.2026.104109_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2026.104109_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2026.104109_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.eclinm.2026.104109_bib10","article-title":"Therapy sequencing in patients with advanced neuroendocrine neoplasms","volume":"43","author":"Riechelmann","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.eclinm.2026.104109_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13443","article-title":"PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)","volume":"37","author":"Sorbye","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.eclinm.2026.104109_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.eclinm.2026.104109_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.amjsurg.2023.08.011","article-title":"Management of neuroendocrine tumor liver metastases","volume":"226","author":"Harrelson","year":"2023","journal-title":"Am J Surg"},{"issue":"S1","key":"10.1016\/j.eclinm.2026.104109_bib14","first-page":"161","article-title":"(EO4) secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive neuroendocrine pancreatic tumour: the OCLURANDOM trial","volume":"37","author":"Baudin","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.eclinm.2026.104109_bib15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1159\/000504001","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors","volume":"110","author":"Jahn","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.eclinm.2026.104109_bib16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cancers13050962","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms","volume":"13","author":"Jahn","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2026.104109_bib17","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/cancers13081936","article-title":"Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3)","volume":"13","author":"Apostolidis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2026.104109_bib18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/onco.13923","article-title":"Temozolomide in grade 3 gastroenteropancreatic neuroendocrine neoplasms: a multicenter retrospective review","volume":"26","author":"Chan","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2026.104109_bib19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104109_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.eclinm.2026.104109_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae178","article-title":"Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phaMe II study","volume":"111","author":"Partelli","year":"2024","journal-title":"Br J Surg"},{"issue":"S7","key":"10.1016\/j.eclinm.2026.104109_bib22","article-title":"LBA45 randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: the SEQTOR study (GETNE 1206)","volume":"33","author":"Salazar","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104109_bib23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104109_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104109_bib25","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"S1","key":"10.1016\/j.eclinm.2026.104109_bib26","first-page":"313","article-title":"(L01) Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial","volume":"37","author":"Capdevila","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.eclinm.2026.104109_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104109_bib28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1159\/000524988","article-title":"Streptozotocin, 1982-2022: forty years from the FDA's approval to treat pancreatic neuroendocrine tumors","volume":"112","author":"Capdevila","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"S2","key":"10.1016\/j.eclinm.2026.104109_bib29","article-title":"1142O multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: the SEQTOR trial (GETNE-1206)","volume":"35","author":"Capdevila Castillon","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104109_bib30","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/cancers17122013","article-title":"Advances in molecular imaging for neuroendocrine neoplasms","volume":"17","author":"Girod","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2026.104109_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13359","article-title":"Use and perceived utility of [(18) F]FDG PET\/CT in neuroendocrine neoplasms: a consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022","volume":"36","author":"Ambrosini","year":"2024","journal-title":"J Neuroendocrinol"},{"issue":"4_suppl","key":"10.1016\/j.eclinm.2026.104109_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS514","article-title":"Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Halfdanarson","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:25:59Z","timestamp":1787559959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S2589537026003627"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104109","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2\u20133, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104109"}}